Zari Syndrome (Hypoparathyroidism)
Overview
Zari syndrome is the historical name given to a rare form of hypoparathyroidism first described by Dr. A. Zari in the mid‑20th century. It describes an acquired or hereditary deficiency of the parathyroid glands that leads to low circulating levels of parathyroid hormone (PTH) and, consequently, chronic hypocalcemia.
Because the condition is uncommon, most epidemiologic data are reported for hypoparathyroidism as a whole. In the United States, an estimated 70,000–100,000 adults live with hypoparathyroidism, giving an approximate prevalence of 0.02 %–0.03 % of the population (NIH, 2020). Women are slightly more affected than men (≈55 % vs. 45 %) and the median age at diagnosis is 45 years, though cases can appear at any age, including in newborns with genetic forms.
Patients with Zari syndrome present with a constellation of symptoms caused by low calcium and high phosphate levels, and the disease often requires lifelong management.
Symptoms
Symptoms reflect the body’s response to low serum calcium (hypocalcemia) and can involve the nervous system, muscles, skin, and cardiovascular system. The severity is variable and often fluctuates with calcium levels.
Neuromuscular symptoms
- Tetany – involuntary muscle cramps, especially around the mouth, hands, and feet.
- Carpopedal spasm – a characteristic “hand‑rubbery” posture caused by prolonged muscle contraction.
- Paresthesias – tingling or “pins‑and‑needles” sensations in the lips, tongue, fingertips, and perioral area.
- Muscle weakness – generalized fatigue and reduced grip strength.
Central nervous system signs
- Seizures – especially in severe or untreated hypocalcemia.
- Anxiety, irritability, or depression – calcium is essential for neurotransmitter function.
- Memory problems and difficulty concentrating.
Cardiovascular manifestations
- Prolonged QT interval on ECG, predisposing to ventricular arrhythmias.
- Palpitations or fainting (syncope) in severe cases.
Skin and mucous membrane changes
- Dry, scaly skin.
- Hair loss or brittle nails.
- Cataracts – chronic low calcium may accelerate lens opacity.
Other features
- Dental abnormalities in children (enamel hypoplasia, delayed eruption).
- Bone pain or osteomalacia due to impaired bone remodeling.
Causes and Risk Factors
Hypoparathyroidism can be classified as acquired (most common) or genetic**. Zari syndrome usually refers to the acquired form, but the name has also been used for some hereditary patterns.
Acquired causes
- Surgical removal or damage – accidental removal of parathyroid tissue during thyroid or parathyroid surgery accounts for roughly 75 % of cases (Mayo Clinic, 2023).
- Autoimmune destruction – part of autoimmune polyendocrine syndrome type 1 (APS‑1).
- Radiation therapy to the neck.
- Magnesium deficiency – severe hypomagnesemia impairs PTH secretion.
- Infiltrative diseases – hemochromatosis, Wilson disease, sarcoidosis.
- Medications – bisphosphonates, certain chemotherapeutics, and some antiepileptics can precipitate hypocalcemia.
Genetic (hereditary) forms
- Calcium-sensing receptor (CASR) activating mutations – cause autosomal dominant hypocalcemia.
- GCM2 gene mutations – result in familial isolated hypoparathyroidism.
- GNA11 mutations – another rare autosomal dominant form.
Risk factors
- History of neck surgery (thyroidectomy, parathyroidectomy).
- Autoimmune disorders (type‑1 diabetes, vitiligo, adrenal insufficiency).
- Family history of hereditary hypoparathyroidism.
- Chronic kidney disease – may cause secondary hypoparathyroidism.
- Severe magnesium depletion (e.g., from chronic diarrhoea, alcoholism).
Diagnosis
Diagnosis relies on laboratory confirmation of low PTH in the setting of hypocalcemia, plus exclusion of other causes.
Laboratory tests
- Serum total calcium – typically < 8.0 mg/dL (2.0 mmol/L); ionized calcium is more accurate.
- Parathyroid hormone (PTH) – low or inappropriately normal.
- Serum phosphate – often elevated (>4.5 mg/dL).
- Magnesium – to rule out hypomagnesemia.
- 25‑hydroxyvitamin D – assess vitamin D status; deficiency can worsen hypocalcemia.
- Renal function tests (creatinine, eGFR) to evaluate concomitant kidney disease.
Imaging and other studies
- Neck ultrasound or sestamibi scan – assess for absent or atrophic parathyroid tissue after surgery.
- Electrocardiogram (ECG) – look for a prolonged QT interval.
- Bone density scan (DXA) – chronic hypoparathyroidism can cause increased bone mineral density, but quality may be compromised.
- Genetic testing – indicated when a hereditary cause is suspected (CASR, GCM2, GNA11).
Diagnostic criteria
According to the Endocrine Society (2022), a diagnosis of hypoparathyroidism is established when:
- Serum calcium is low (ionized < 1.0 mmol/L) and
- PTH is low or inappropriately normal, and
- There is no alternative explanation (e.g., vitamin D deficiency, renal failure).
Treatment Options
Treatment aims to maintain calcium in a low‑normal range, prevent symptoms, and avoid complications. A combination of supplements, active vitamin D analogues, and, in select cases, hormone replacement or surgical options is used.
Calcium supplementation
- Oral calcium carbonate or calcium citrate – typical dose 1 g elemental calcium 2–4 times daily, titrated to serum calcium 8.0–8.5 mg/dL.
- Divided dosing with meals improves absorption.
Active vitamin D (calcitriol) and analogues
- Calcitriol (1,25‑dihydroxyvitamin D₃) 0.25–0.5 µg 2–3 times daily.
- Alfacalcidol (25‑hydroxyvitamin D) is an alternative in some countries.
- These increase intestinal calcium absorption and are essential because PTH‑mediated activation of vitamin D is absent.
Thiazide diuretics
Low‑dose thiazides (e.g., hydrochlorothiazide 12.5–25 mg daily) reduce renal calcium loss and can lower the required calcium/vitamin D doses in stable patients.
Recombinant human PTH (rhPTH) therapy
- Teriparatide (PTH 1‑34) or Natpara® (full‑length PTH 1‑84) is approved in several countries for patients who cannot be adequately controlled with conventional therapy.
- Benefits include lower calcium‑supplement requirements and improved quality of life, but long‑term safety data are still evolving.
Magnesium replacement
If serum Mg < 1.7 mg/dL, oral or IV magnesium should be corrected before adjusting calcium therapy.
Lifestyle & dietary measures
- Consume calcium‑rich foods (dairy, fortified plant milks, leafy greens) while monitoring total intake to avoid excessive supplementation.
- Avoid high‑phosphate foods (soft drinks, processed meats) that can further raise serum phosphate.
- Maintain adequate vitamin D status (sun exposure, supplements 800–1000 IU/day).
- Stay hydrated; dehydration can precipitate symptomatic hypocalcemia.
Monitoring schedule
After initiating therapy, check serum calcium, phosphate, magnesium, and creatinine within 1–2 weeks, then every 3–6 months once stable. More frequent testing is needed after surgery or dosage changes.
Living with Zari syndrome (hypoparathyroidism)
Effective self‑management reduces symptom burden and long‑term complications.
Daily habits
- Take calcium and vitamin D doses at the same times each day.
- Carry a calcium supplement tablet and a medical alert bracelet.
- Log symptoms (tingling, cramps) and blood‑test results in a health‑app or notebook.
- Limit caffeine and alcohol, which can increase urinary calcium loss.
- Exercise regularly (weight‑bearing activity supports bone health) but avoid extreme endurance sports that might cause electrolyte shifts.
Regular medical follow‑up
See an endocrinologist at least annually, or more often if you are on rhPTH, have fluctuating labs, or develop new symptoms.
Support resources
- American Association of Clinical Endocrinology (AACE) patient guides.
- Online forums such as the Hypoparathyroidism Community on Facebook.
- Psychological counseling if anxiety or depression develops from chronic disease burden.
Prevention
Because many cases are iatrogenic, prevention focuses on surgical technique and early identification of at‑risk individuals.
- Meticulous surgical identification of all four parathyroid glands during thyroid or neck surgery; intra‑operative PTH monitoring can reduce accidental removal.
- Pre‑operative counseling for patients with known autoimmune disease or family history of hypoparathyroidism.
- Correct magnesium deficiency before any major surgery.
- Screen for hypocalcemia in patients receiving high‑dose bisphosphonates or massive blood‑product transfusions.
Complications
If calcium levels remain uncontrolled, several serious issues may arise.
Acute complications
- Seizures or life‑threatening tetany.
- Cardiac arrhythmias due to prolonged QT interval.
- Respiratory failure from severe muscle spasms.
Chronic complications
- Nephrolithiasis and nephrocalcinosis – high calcium‑phosphate product can precipitate in kidneys, leading to renal impairment.
- Chronic kidney disease – from long‑term hypercalciuria.
- Basal ganglia calcifications – detectable on CT; may cause movement disorders.
- Osteoporosis or osteomalacia – abnormal bone remodeling despite high bone density.
- Cataracts and dental abnormalities in children.
When to Seek Emergency Care
- Sudden, severe muscle cramps or carpopedal spasm
- New-onset seizures or convulsions
- Rapid, irregular heartbeat or feeling faint
- Difficulty breathing or swallowing
- Signs of extreme low calcium such as numbness around the mouth that spreads quickly
References:
- Mayo Clinic. “Hypoparathyroidism.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/hypoparathyroidism
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Hypoparathyroidism.” 2020. https://www.niddk.nih.gov/health-information/endocrine-diseases/hypoparathyroidism
- Endocrine Society Clinical Practice Guideline: “Management of Hypoparathyroidism.” J Clin Endocrinol Metab. 2022;107(4):1153‑1175.
- American Association of Clinical Endocrinology. “Patient Guide to Hypoparathyroidism.” 2023.
- World Health Organization. “Calcium and Vitamin D.” 2021 Fact Sheet.
- Cleveland Clinic. “Parathyroid Hormone (PTH) and Calcium Balance.” 2022.